Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-44583
Grünblatt, E; Schmidt, W J; Scheller, D K A; Riederer, P; Gerlach, M (2011). Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats. Journal of Neural Transmission, 118(12):1717-1725.
- Registered users only
Continuous dopaminergic treatment is considered to prevent or delay the occurrence of dyskinesia in patients with Parkinson's disease (PD). Rotigotine is a non-ergolinic D(3) > D(2) > D(1) dopamine-receptor agonist for the treatment of PD using a transdermal delivery system providing stable plasma levels. We aimed to investigate the differential influence on gene expression of pulsatile L: -DOPA or rotigotine versus a continuous rotigotine treatment. The gene expression profile within the nigro-striatal system of unilateral 6-hydroxydopamine-lesioned rats was assessed in order to differentiate potential changes in gene expression following the various treatment using Affymetrix microarrays and quantitative RT-PCR. The expression of 15 genes in the substantia nigra and of 11 genes in the striatum was altered under pulsatile treatments inducing dyskinetic motor response, but was unchanged under continuous rotigotine treatment that did not cause dyskinetic motor response. The route of administration of a dopaminergic drug is important for the induction or prevention of motor abnormalities and adaptive gene expressions. The decline of neurotrophin-3 expression under pulsatile administration was considered of particular importance.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Center for Child and Adolescent Psychiatry|
|DDC:||610 Medicine & health|
|Deposited On:||04 Feb 2011 15:52|
|Last Modified:||28 Nov 2013 00:27|
|Citations:||Web of Science®. Times Cited: 4|
Scopus®. Citation Count: 4
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page